”On behalf of the Recordati group, Robert Desnick, Francesco Emma, Norio Sakai, and myself, it is an honour and a privilege to award Alberto Auricchio’s outstanding research project that could potentially reduce the impact of an extremely severe rare disease and provide needed therapies” declared Andrea Recordati, Chief Executive Officer.